IRVINE, Calif. and LONDON, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Lombard Medical, Inc (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that CEO Simon Hubbert is scheduled to present at the following upcoming investor conferences:
- The Barclays MedTech SMID Cap Conference on November 3, 2014, in New York City.
- The Credit Suisse Healthcare Conference on November 11, 2014, at 3:30 p.m. in Phoenix.
- The Stifel 2014 Healthcare Conference on November 19, 2014, at 4:10 p.m. in New York City.
- The Canaccord Genuity Medical Technology & Diagnostics Conference on November 20, 2014, at 8:20 a.m. in New York City.
A live audio webcast of the presentations at the Credit Suisse, Stifel and Canaccord Genuity conferences will be available on the Events and Presentations page of the Investors section of Lombard Medical's website at www.lombardmedical.com.
About Lombard Medical, Inc.
Lombard Medical, Inc. is a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm repair market. The Company's lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Lombard Medical, Inc. is based in Oxfordshire, England with U.S. commercial headquarters in Irvine, CA and is registered in the Cayman Islands.
This announcement may contain forward-looking statements that reflect the Company's current expectations regarding future events, including the commercialization and additional regulatory clearances of the Company's products, the Company's liquidity and results of operations, as well as future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company's products by hospitals and other medical professionals and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's prospectus filed with the Securities and Exchange Commission dated April 25, 2014. The Company undertakes no obligation to update these statements in the future.
|For further information:|
|Lombard Medical, Inc.|
|Simon Hubbert, Chief Executive Officer||Tel: +1 949 379 3750|
|Ian Ardill, Chief Financial Officer||Tel: +44 (0)1235 750 800|
|Pure Communications||Tel: +1 949 370 8500|
|Matthew H Clawsonemail@example.com|
|FTI Consulting (UK)||Tel: +44 (0)20 3727 1000|
|Simon Conway, Victoria Foster Mitchell|
Source:Lombard Medical, Inc.